Bodenhoff Mads's Form 4 filing
Ascendis Pharma A/S (ASND) · filed Sep 9, 2026
- Accession no.
- 0001610717-26-000409
- Filed
- Sep 9, 2026, 5:04 PM ET
- Trade date
- Sep 8, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $810.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bodenhoff MadsCIK 0002014697 | Officer (SVP & PAO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Ordinary Shares | MOption exerciseAcquired | +3,000 | $110.00 | +$330,000 | 3,000 | Direct | |
| Sep 8, 2026 | Ordinary Shares | SSaleDisposed | −3,000 | $270.19 | −$810,570 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Ordinary Shares | MOption exerciseDisposed | −3,000 | $0.00 | $0 | 687 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.